The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Pilot study of the 5-HT 2A R agonist psilocybin in the treatment of tobacco addiction
Open accessAbstract
Despite suggestive early findings on the therapeutic use of hallucinogens in the treatment of substance use disorders, rigorous follow-up has not been conducted. To determine the safety and feasibility of psilocybin as an adjunct to tobacco smoking cessation treatment we conducted an open-label pilot study administering moderate (20 mg/70 kg) and high (30 mg/70 kg) doses of psilocybin within a structured 15-week smoking cessation treatment protocol. Participants were 15 psychiatrically healthy nicotine-dependent smokers (10 males; mean age of 51 years), with a mean of six previous lifetime quit attempts, and smoking a mean of 19 cigarettes per day for a mean of 31 years at intake. Biomarkers assessing smoking status, and self-report measures of smoking behavior demonstrated that 12 of 15 participants (80%) showed seven-day point prevalence abstinence at 6-month follow-up. The observed smoking cessation rate substantially exceeds rates commonly reported for other behavioral and/or pharmacological therapies (typically <35%). Although the open-label design does not allow for definitive conclusions regarding the efficacy of psilocybin, these findings suggest psilocybin may be a potentially efficacious adjunct to current smoking cessation treatment models. The present study illustrates a framework for future research on the efficacy and mechanisms of hallucinogen-facilitated treatment of addiction.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Psychedelic-assisted therapies currently offer one of the most robust experimental models for eliciting ST, frequently occasioning ego-dissolution and mystical-type experiences that are associated with sustained reductions in depression, anxiety, and addictive behaviors (97, 106).”
From The therapeutic role of self-transcendence in moral injury recovery: theory, mechanisms, and clinical implications (2026) · cites this paper as [106]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A single-arm pilot study of PAT to treat tobacco use disorder found 67% and 60% of people remained abstinent at 12 and ≥16 months of follow-up [54].”
From Psilocybin‐assisted psychotherapy for methamphetamine use disorder: A pilot open‐label safety and feasibility study. (2025) · cites this paper as [54]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“These findings demonstrate the likely feasibility of conducting such treatment in a substance use disorder [25,54].”
From Psilocybin‐assisted psychotherapy for methamphetamine use disorder: A pilot open‐label safety and feasibility study. (2025) · cites this paper as [54]
In the citing paper
“In an open-label pilot study, 12 out of 15 treatment-seeking smokers were nicotine abstinent 6 months after two to three administrations of psilocybin (26).”
From Modulation of Social Cognition via Hallucinogens and “Entactogens” (2019) · cites this paper as [26]
In the citing paper
“Facilitating the reconnection with their social environment via increased emotional empathy may therefore contribute to clinical efficacy of hallucinogens shown in preliminary studies with addicted patients (24, 26).”
From Modulation of Social Cognition via Hallucinogens and “Entactogens” (2019) · cites this paper as [26]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Fagerstrom Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire
HEATHERTON, T. F., KOZLOWSKI, L. T., FRECKER, R. C., & FAGERSTROM, K. (1991) · British Journal of Addiction · doi:10.1111/j.1360-0443.1991.tb01879.x · Cited by 10,738 · cited 1×
“The Fagerström Test for Cigarette Dependence (FTCD; formerly Fagerström Test for Nicotine Dependence) is a 6-item questionnaire widely used to characterize the level of dependence of cigarette smokers (Fagerström, 2012; Heatherton et al., 1991).”
Method(2008) · Medical Entomology and Zoology · Cited by 7,477
The Health consequences of smoking—50 years of progress : a report of the Surgeon General
Lushniak, B. D., Samet, J. M., Pechacek, T. F., Norman, L., & Taylor, P. A. (2014) · Cited by 4,990
Sobell, L. C., & Sobell, M. B. (1992) · Measuring Alcohol Consumption · doi:10.1007/978-1-4612-0357-5_3 · Cited by 4,110 · cited 1×
“The TLFB is a self-report calendar completed retrospectively by participants indicating the number of cigarettes smoked each day (Sobell and Sobell, 1992).”
BackgroundThe Health Consequences of Smoking -- 50 Years of progress: A Report of the Surgeon General
General, U. S. S. (2014) · PsycEXTRA Dataset · doi:10.1037/e510072014-001 · Cited by 3,368
Biochemical verification of tobacco use and cessation
Benowitz, N. L., III, P. J., Ahijevych, K., Jarvis, M. J., Hall, S., LeHouezec, J., Hansson, A., Lichtenstein, E., Henningfield, J., Tsoh, J., et al. (2002) · Nicotine & Tobacco Research · doi:10.1080/14622200210123581 · Cited by 1,800 · cited 1×
“Two measures of recent smoking, exhaled carbon monoxide (CO) and urinary cotinine level (Benowitz et al., 2002), were assessed at intake, weekly throughout the intervention, and at 6-month follow-up.”
Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0457-5 · Cited by 1,684 · cited 7×
“This 100- item questionnaire has previously been used to characterize the subjective effects of psilocybin (Griffiths et al., 2006, 2011).”
BackgroundMethodResultInfluentialSelf-citationJorenby, D. E. (2006) · JAMA · doi:10.1001/jama.296.1.56 · Cited by 1,635 · cited 3×
“For example, when paired with 12 brief weekly counseling meetings, pharmacotherapies have shown seven-day point prevalence abstinence rates of 24.9% to 26.3% (bupropion) and 33.5% to 35.2% (varenicline) at approximately 6 months post-TQD (Gonzales et al., 2006; Jorenby et al., 2006).”
BackgroundInfluentialGonzales, D. (2006) · JAMA · doi:10.1001/jama.296.1.47 · Cited by 1,361 · cited 3×
“For example, when paired with 12 brief weekly counseling meetings, pharmacotherapies have shown seven-day point prevalence abstinence rates of 24.9% to 26.3% (bupropion) and 33.5% to 35.2% (varenicline) at approximately 6 months post-TQD (Gonzales et al., 2006; Jorenby et al., 2006).”
BackgroundInfluentialCarhart-Harris, R. L., Leech, R., Hellyer, P. J., Shanahan, M., Feilding, A., Tagliazucchi, E., Chialvo, D. R., & Nutt, D. (2014) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2014.00020 · Cited by 1,252 · cited 1×
“Several plausible mechanisms of hallucinogen-facilitated treatments have been proposed (Bogenschutz and Pommy, 2012; Carhart-Harris et al., 2012, 2014; Ross, 2012; Vollenweider and Kometer, 2010).”
Background
Research works printed but not linked: 4
- Griffiths RR, 1980, Adv Subst Abuse, 1, 1
- Marks DF, 1993, The QUIT FOR LIFE Programme: An easier way to stop smoking and not start again
- National Institute on Drug Abuse, 2005, LSD NIDA Infofacts
- World Health Organization, 2011, WHO report on the global tobacco epidemic, 2011: Warning about the dangers of tobacco
Cited by
Sorted by citations
Items 701–800 of 914
Jones, G. M., Lipson, J., & Wang, E. (2023) · Scientific Reports · doi:10.1038/s41598-023-29763-x · Cited by 3
Silva, J., Garcia, J., Guimarães, R., Palito, C., Lemos, A. M., Barros, L., & Alves, M. J. (2023) · Springer eBooks · doi:10.1007/978-3-031-18587-8_16 · Cited by 3
Psilocybin to promote synaptogenesis in the brains of patients with mild cognitive impairment
Song, J., Kambari, Y., Amaev, A., Ueno, F., Carmona, E. T., Luca, V. D., Pollock, B. G., Flint, A. J., Husain, M. I., Graff‐Guerrero, A., et al. (2023) · Medical Hypotheses · doi:10.1016/j.mehy.2023.111068 · Cited by 4
Bis(4-acetoxy- N -ethyl- N - n -propyltryptammonium) fumarate–fumaric acid (1/1)
Pham, D. N. K., Sackett, N. B., Chadeayne, A. R., Golen, J. A., & Manke, D. R. (2023) · IUCrData · doi:10.1107/s2414314623007794 · Cited by 2
Can a single dose of psilocybin improve cognitive control in functional dissociative seizures?
Chupin, J., López‐Castromán, J., Brière, C., Pereira, F., Hingray, C., & Conejero, I. (2023) · Medical Hypotheses · doi:10.1016/j.mehy.2023.111163 · Cited by 2
If Everything Is Psychedelic, Then Nothing Is: A Response to O'Donnell et al. and Lepow et al.
Nichols, D. E., Hendricks, P. S., & Nichols, C. D. (2023) · Psychedelic Medicine · doi:10.1089/psymed.2023.29003.cdn · Cited by 2
Unveiling the Psychedelic Journey: An Appraisal of Psilocybin as a Profound Antidepressant Therapy
Shah, F. I., Shehzadi, S., Akram, F., Haq, I. U., Javed, B., Sabir, S., Kazim, Y., & Ashfaq, S. (2023) · Molecular Biotechnology · doi:10.1007/s12033-023-00994-7 · Cited by 4
“This has led to the emergence of a flourishing medical psychedelic tourism industry, such as Atman and Mycomeditations retreats [101].”
Disorders due to Substance Use: Hallucinogens and MDMA-Related Substances
Nayak, S. M., & Johnson, M. W. (2023) · Springer eBooks · doi:10.1007/978-3-030-42825-9_94-1 · Cited by 2
Self-citationAt the Forefront: Social Workers’ Role in Psilocybin Treatment for Depression and Substance Misuse
Parker, C., & Wood, B. M. (2024) · Social Work · doi:10.1093/sw/swae019 · Cited by 4
Dost, D., Benyamina, A., & Karila, L. (2024) · L Encéphale · doi:10.1016/j.encep.2024.02.007 · Cited by 2
Disorders due to Substance Use: Hallucinogens and MDMA-Related Substances
Nayak, S. M., & Johnson, M. W. (2024) · Springer eBooks · doi:10.1007/978-3-030-51366-5_94 · Cited by 2
Self-citationFernandes-Nascimento, M. H., Viana-Ferreira, K., & Negrão, A. B. (2025) · Psychedelic Medicine · doi:10.1089/psymed.2024.0031 · Cited by 2
Miller, C. W. T., & Kozak, Z. (2025) · Harvard Review of Psychiatry · doi:10.1097/hrp.0000000000000425 · Cited by 2
Is there a place for psychedelics in sports practice?
Portes, M. A. M., Werle, I., & Bertoglio, L. J. (2025) · Acta Neuropsychiatrica · doi:10.1017/neu.2025.13 · Cited by 3
Race/ethnicity moderates the associations between lifetime psilocybin use and opioid use disorder
Jones, G. M. (2025) · PLoS ONE · doi:10.1371/journal.pone.0321461 · Cited by 2
Morland, L. A., Knopp, K. C., Khalifian, C. E., & Stauffer, C. S. (2025) · Cognitive and Behavioral Practice · doi:10.1016/j.cbpra.2025.04.001 · Cited by 2
Johnson, S., & Black, Q. C. (2020) · International Journal of Mental Health and Addiction · doi:10.1007/s11469-020-00398-7 · Cited by 4
Do Hallucinogens Have a Role in the Treatment of Addictions? A Review of the Current Literature
Nigam, K. B., & Pandurangi, A. K. (2021) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-021-00871-x · Cited by 2
Pharmacological assistance for psychotherapy
Lochtenberg, J., Kirshenbaum, A. P., & Johnson, M. W. (2021) · Emerging Trends in Drugs Addictions and Health · doi:10.1016/j.etdah.2021.100017 · Cited by 2
Self-citationCould Psychedelics Treat Neuropathic Chronic Pain?
(2023) · Neurological Sciences and Neurosurgery · doi:10.47275/2692-093x-130 · Cited by 1
“Psychedelics including LSD and psilocybin have mild, transient physiological effects [50,51].”
BackgroundClarifying the relationship between social connectedness and connectedness to nature
Moreton, S. G. (2018) · The Sydney eScholarship Repository (The University of Sydney) · Cited by 2
Hopper, J. W. (2020) · Journal of Trauma & Dissociation · doi:10.1080/15299732.2020.1718968 · Cited by 2
Finkelstein, C., Soha, O., Roy, A., Phillipou, A., & Rossell, S. L. (2023) · Research Square · doi:10.21203/rs.3.rs-3189970/v1 · Cited by 2
Psychedelic Therapy: Beyond Brain, Embracing CulturePreprint
Hipólito, I., & Tzima, S. (2023) · doi:10.31234/osf.io/rjngs · Cited by 2
Large language models auto-profile conscious awareness changes under psychedelic drug effectsPreprint
Bzdok, D., Carhart-Harris, R. L., Savignac, C., Bell, G., & Laureys, S. (2024) · Research Square · doi:10.21203/rs.3.rs-4670805/v1 · Cited by 3
Mennenga, S. E., Hanson, T., Semple, M. G., Lifshitz, D., Flores, B., Balducci, J., Harker, S. A., Ford, A., & Lewis, C. R. (2025) · Research Square · doi:10.21203/rs.3.rs-7890051/v1 · Cited by 2
Strika-Bruneau, L., Fauvel, B., Dupuis, D., & Benyamina, A. (2023) · L Évolution Psychiatrique · doi:10.1016/j.evopsy.2023.01.003 · Cited by 1
Čampara, A., & Kovačić, D. (2024) · World Congress on Medical Physics and Biomedical Engineering, September 7 - 12, 2009, Munich, Germany · doi:10.1007/978-3-031-49068-2_54 · Cited by 1
The way of O: phenomenology of psychedelic use and the path to ultimate reality
Miller, C. W. T. (2024) · Psychodynamic Practice · doi:10.1080/14753634.2024.2371787 · Cited by 2
“…findings emerging for conditions such as substance use disorders (Armstrong et al., 2023; Bogenschutz et al., 2015; Hendricks et al., 2014; Johnson et al., 2014; Tap, 2024), depression and anxiety (including in individuals with serious and terminal medical conditions) (Carhart-Harris et…”
Drugs Under Clinical Trials for the Treatment of Migraine
Devadoss, T., & Pingili, R. B. (2024) · Springer eBooks · doi:10.1007/978-981-97-4529-6_12 · Cited by 1
Social Worker Attitudes towards Psychedelics
Nowakowski-Sims, E., & Holzworth, J. (2025) · Clinical Social Work Journal · doi:10.1007/s10615-025-00988-9 · Cited by 2
“…in depression (Carhart-Harris et al., 2016; Davis et al., 2022; Ross et al., 2016), PTSD (Mitchell et al., 2023; Mithoefer et al., 2019), eating disorders (Calder et al., 2023) addiction (Bogenschutz et al., 2015; Johnson et al., 2014) and anxiety (Holze et al., 2023; Ross et al., 2016).”
Considerations on the Construction, Timing, and Consequences of the Psychedelic Renaissance
Dollar, C. B. (2025) · Contemporary Drug Problems · doi:10.1177/00914509251344637 · Cited by 3
“…al., 2014; Grob et al., 2011), obsessive compul-sivity and depression (Moreno et al., 2006), and other symptoms related to addiction withdrawal (Bogenschutz & Pommy, 2012; Bogenschutz et al., 2015; Dyck, 2008; Halpern, 1996; Johnson et al., 2014; Krebs & Johansen, 2013; Mangini, 1998; Ross, 2013).”
Glenn, D. L., Choi, S. H., & Zimmerman, R. S. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811251353251 · Cited by 1
“One study used purposive sampling (e.g., nicotine-dependent smokers with long-term smoking habits; Johnson et al., 2014, 2017b).”
InfluentialPsychedelic studies in nonhuman primates: Past and future
Masthay, J. C., Kwan, A. C., & Chang, S. W. C. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03240-5 · Cited by 2
“Similarly, in clinical trials, psilocybin showed ef fi cacy in treating alcohol use disorder [1] and promoting cessation of tobacco smoking [76].”
Exploring the effects of microdosing on health behaviour change
Prochazkova, L., de Carvalho, L. L., Marrouch, N., Encantado, J., & Teixeira, P. J. (2025) · Neuropharmacology · doi:10.1016/j.neuropharm.2025.110688 · Cited by 3
High Risk, Low Key: The New Face of Drug Use
Burmeister, J., & Jung, J. K. (2025) · Substance Use Research and Treatment · doi:10.1177/29768357251389682 · Cited by 1
“23 Using psilocy-bin or kratom informally to mitigate harms from illicit drugs remains risky and unproven.”
de Carvalho, L. L., Encantado, J., van Elk, M., Moller, A. C., Cornelius, T. M., Timmermann, C., Veiga, D., & Teixeira, P. J. (2025) · Scientific Reports · doi:10.1038/s41598-025-25818-3 · Cited by 1
“For tobacco cessation or reduction there is also evidence from both clinical trials 15 and observational studies 16–”
Psilocybin-assistierte Gruppenpsychotherapie bei Abhängigkeitserkrankungen
Wopfner, A., & Soravia, L. M. (2025) · SUCHT - Zeitschrift für Wissenschaft und Praxis / Journal of Addiction Research and Practice · doi:10.1024/0939-5911/a000956 · Cited by 1
Disengaged: A systematic review of community engagement in psychedelic-assisted therapy research
Reid, M. R., Song, J., Boehnke, K. F., Buchanan, N. T., & Aday, J. S. (2025) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2025.106516 · Cited by 1
Exploring Access to Psychedelics Among Canadian Veterans: Pathways, Barriers, and Perceptions
Contreras, L. E., Elliott, G., Kment, F., Scott, M. A., Fascinato, D., & Mayo, L. M. (2025) · Psychedelic Medicine · doi:10.1177/28314425251387678 · Cited by 1
Mehmood, M., Bremler, R., Spriggs, M. J., Kettner, H., Roseman, L., Damgaard, L., Carhart-Harris, R. L., Erritzøe, D., & Zeifman, R. J. (2025) · Psychedelic Medicine · doi:10.1177/28314425251392251 · Cited by 2
Associations of Couples’ Psychedelic Use with Shared Reality and Relational Well-Being
Cornelius, T. M., & Barba, T. (2026) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2025.2607729 · Cited by 1
Lodetti, G., Réus, G. Z., & Rico, E. P. (2026) · Neuroscience · doi:10.1016/j.neuroscience.2026.01.022 · Cited by 1
Psychedelic-assisted psychotherapy: Clarifying the role of the "psychotherapy"
Jerotić, S., Čolović, O., & Marić, N. P. (2026) · Medicinska istrazivanja · doi:10.5937/medi0-62051 · Cited by 2
Psychological support in psychedelic-assisted therapy clinical trials: A systematic review
Brusky, B., M’Baïlara, K., Alla, F., & Barrault, M. (2026) · Journal of Psychopharmacology · doi:10.1177/02698811261424204 · Cited by 1
“In some cases, the choice of psychotherapeutic technique was justified by past research suggesting effectiveness with the treatment population (Danforth et al., 2018; Johnson et al., 2014).”
InfluentialDeutsch, A., Contreras, L. E., Kratina, S., & Mayo, L. M. (2026) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253261433836 · Cited by 1
Kittirattanapaiboon, C., SHOPTAW, S. J., Mayes, T. L., Jha, M. K., Ghitza, U. E., & Trivedi, M. H. (2026) · Journal of Substance Use and Addiction Treatment · doi:10.1016/j.josat.2026.209994 · Cited by 1
Trials, trips, and tribulations: pathways for implementing psychedelic therapy in Ireland
Kelly, J. R., Sheridan, C., Iusan, P., Coakley, L., Burke, L., Brennan, C., MacDonald, A. A., Ivers, J., Trépel, D., Tormey, G., et al. (2026) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyag028 · Cited by 1
Wei, L., Chen, H., & Li, Y. (2026) · Journal of Raman Spectroscopy · doi:10.1002/jrs.70178 · Cited by 1
Postránecká, Z., Lucký, M., Mravčík, V., & Páleníček, T. (2026) · Journal of Psychedelic Studies · doi:10.1556/2054.2026.00514 · Cited by 1
Psychedelics and longevity: implications for lifespan, healthspan and functional aging
Haden, M., Woods, B., Woods, T., & Tupper, K. W. (2026) · Longevity · doi:10.1080/30653495.2026.2696224 · Cited by 1
Strika-Bruneau, L., Elhssaini, C., Fauvel, B., Kervadec, E., Bezo, A., Amirouche, A., Benyamina, A., & Roméo, B. (2026) · Journal of Psychopharmacology · doi:10.1177/02698811261473436 · Cited by 1
The rebirth of psychedelic psychiatry
Holoyda, B. J. (2021) · Current Psychiatry · doi:10.12788/cp.0079 · Cited by 1
Ovies, D. H. (2021) · Perspectiva geográfica · doi:10.19053/01233769.12400 · Cited by 1
Is MDD the right target for early-stage psychedelic-assisted therapy trials?
Lewis, B. R., & Byrne, K. (2021) · Journal of Psychedelic Studies · doi:10.1556/2054.2021.00180 · Cited by 1
Neuropharmacological analysis of the anti-addictive and therapeutic effects of psilocybin
Principe, A. (2022) · SURG Journal · doi:10.21083/surg.v14i1.6870 · Cited by 1
Lasch, A., Schweikert, T., Dora, E., Kolb, T., Schurig, H. L., & Walther, A. (2023) · Fortschritte der Neurologie · Psychiatrie · doi:10.1055/a-2046-5202 · Cited by 1
THE SEROTONIN 5-HT2ARECEPTOR AS AN EVOLVING NEUROTHERAPEUTIC TARGET
Bolinger, A. A., Anastasio, N. C., Cunningham, K. A., & Zhou, J. (2023) · Medicinal chemistry reviews · doi:10.1021/mc-2023-vol58.ch03 · Cited by 1
Psychedelic Healing: A Historical, Empirical, and Personal Account
Swoap, R. (2023) · American Journal of Health Promotion · doi:10.1177/08901171231210806e · Cited by 1
Psychedelic integration and transformation
Branco, J. (2023) · Consciousness Spirituality & Transpersonal Psychology · doi:10.53074/cstp.2023.66 · Cited by 1
Xie, Y., Xue, F., Tao, J., Gao, Q., Li, Y., Liu, X., Xia, M., & Wang, D. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.129539 · Cited by 1
Pharmacotherapy of Psychological Disorders Using Psychedelic Drugs: A Treatise for Psychiatrists
Ghosh, P., & Sur, D. (2024) · Current Psychiatry Research and Reviews · doi:10.2174/0126660822258502231120074036 · Cited by 1
Sekula, A. D., Puspanathan, P., Downey, L. A., & Liknaitzky, P. (2024) · Psychoactives · doi:10.3390/psychoactives3020010 · Cited by 2
“…in understanding of the meaning of life [20,26,27], sense of purpose [26], qualitative improvements in respondents’ self-perception [22,31,33], greater insight into one’s addiction [32,33], increased urgency for abstinence [33], increased spirituality [20,22], and increased self-efficacy [32].”
BackgroundInfluentialTherapeutic Implications of Psilocybin in the Wake of Decriminalization
Lash, N., Tadros, G., & Tadros, E. (2024) · Integrative and Complementary Therapies · doi:10.1089/ict.2024.27206.nl · Cited by 1
Toxin Concerns and Safe Consumption of Edible Mushroom
Ogidi, O. I., & Adigwe, P. C. (2025) · Reference series in phytochemistry · doi:10.1007/978-3-031-52642-8_39-1 · Cited by 1
Do undergraduates’ views of psychedelics relate to the context for psychedelic use?
Petrovitch, D., Allen, J. V., Mitchell, S. M., & Littlefield, A. K. (2025) · Drug Science Policy and Law · doi:10.1177/20503245241308747 · Cited by 2
“These psychedelic-assisted therapies occur in controlled, supportive environments (e.g., research clinics; Bogenschutz et al., 2015; Johnson et al., 2014).”
Barnett, B. S., Anand, A., Weleff, J., King, F., & Dewey, E. N. (2025) · Psychedelic Medicine · doi:10.1177/28314425251367321 · Cited by 1
My Experience as a Guide in the Johns Hopkins Psilocybin Research Project
Cosimano, M. P. (2014) · Cited by 1
Self-citationKähönen, J. (2020) · Työväentutkimus Vuosikirja · Cited by 1
Garcia, S. A., & Márquez, C. I. (2021) · Genealogy · doi:10.3390/genealogy5020053 · Cited by 1
“Quitting alcohol and tobacco may also be progressed with psilocybin-assisted treatment models (Bogenschutz et al. 2015; Johnson et al. 2014).”
Kang, M., Mackay, L., Christie, D., Callon, C., & Argento, E. (2022) · Journal of Psychedelic Studies · doi:10.1556/2054.2022.00190 · Cited by 1
The Buddhist Noble Truths: Are They True?
Bronkhorst, J. (2023) · Religions · doi:10.3390/rel14010082 · Cited by 3
Psilocybin Therapy for Major Depressive Disorder: A Systematic Review
Venugopal, K. (2023) · Undergraduate Research in Natural and Clinical Science and Technology (URNCST) Journal · doi:10.26685/urncst.489 · Cited by 1
“Despite its low propensity to cause physical or psychological addiction, [46-47] further research is necessary to comprehend the long-term effects of psilocybin and establish effective protocols for its therapeutic use and research.”
BackgroundPsilocybin-Assisted Psychotherapy: Treating Depression and Anxiety with Mushrooms
Beck, S. (2020) · doi:10.33015/dominican.edu/2020.pas.10 · Cited by 1
“In fact, studies of alcohol and smoking cessation indicate psilocybin may have antiaddictive properties.(16,17) These findings suggest that it can be safely administered to patients in a”
BackgroundA Needs Assessment of Older Hispanics in Omaha, Nebraska
DiMartino, D. R. (1979) · DigitalCommons@UNO · Cited by 1
UK drugs strategy promises to be tough on criminals, but evidence shows this doesn't work
Nutt, D. (2021) · BMJ · doi:10.1136/bmj.n3066 · Cited by 1
Nichols, D. E., & Nichols, C. D. (2021) · Springer eBooks · doi:10.1007/978-3-030-57401-7_10034 · Cited by 1
Ozols, A. B., Wei, J., Campbell, J. M., Hu, C., Qiu, S., & Gallitano, A. L. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.05.21.595211 · Cited by 1
Lane, C. P., Tarka, V., Valentin, O., Lehmann, A., Hamel, É., & de Villers‐Sidani, E. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.09.27.614985 · Cited by 1
“Promising results from several clinical trials have accelerated clinical interest in psychedelics to treat conditions such as depression 3–6 , addiction 7–10 and anxiety 3,11–14 .”
BackgroundSemple, M. G., Mennenga, S. E., Smith, R. C., Dwaraka, V. B., Cahn, B. R., Tafur, J., Rabin, D. M., Yazar‐Klosinski, B., & Lewis, C. R. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.07.03.663007 · Cited by 1
Fleming, W. H. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2026.1701564
“Psychedelic-assisted therapies currently offer one of the most robust experimental models for eliciting ST, frequently occasioning ego-dissolution and mystical-type experiences that are associated with sustained reductions in depression, anxiety, and addictive behaviors (97, 106).”
Shelby, C. L. (2016) · Palgrave Macmillan UK eBooks · doi:10.1057/9781137552853_8
Can 3,4,-methylenedioxymethamphetamine therapy be used to treat alcohol use disorder?
Sessa, B. (2017) · Journal of Psychedelic Studies · doi:10.1556/2054.01.2016.003
Geschichte der Psychedelika in der Medizin
Sessa, B. (2017) · Springer eBooks · doi:10.1007/978-3-642-55125-3_99
Psychedelic therapy as a complementary treatment approach for alcohol use disorders
Eischens, P., & Atherton, W. L. (2018) · Journal of Psychedelic Studies · doi:10.1556/2054.2018.005 · Cited by 3
Exploring the Therapeutic Potential of Psychedelics
Hernandez, X. M. (2018) · Undergraduate Research Journal
Innovative pharmakologische Ansätze zur Behandlung von Suchterkrankungen
Majić, T., Gutwinski, S., Müller, C. A., Schoofs, N., & Heinz, A. (2018) · Elsevier eBooks · doi:10.1016/b978-3-437-23021-9.00006-0
Meil, W. M., Farrell, W., & Satti, R. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.98514
ルポ 昼休みを生かしてリフレッシュ--東京急行電鉄(株)車両部長津田検車区 (作業の合間でリフレッシュ--休憩時間の過ごし方のヒント )
労働衛生編集部 (1995) · 労働衛生
Geschichte der Psychedelika in der Medizin
Sessa, B. (2017) · Springer eBooks · doi:10.1007/978-3-642-55214-4_99-1
Let’s Take a Trip into Mental Health
Castello, A. (2022) · Berkeley Scientific Journal · doi:10.5070/bs326157110
Bonson, K. R. (2020) · Wiley eBooks · doi:10.1002/9780470015902.a0029200
Nichols, D. E., & Nichols, C. D. (2021) · Springer eBooks · doi:10.1007/978-3-030-21573-6_10034-1
Unravelling a New Conformer of Psilocin Through Computational MethodsPreprint
Bhadoria, P., & Ramanathan, V. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4162669
РЕНЕСАНС ПСИХОДЕЛІЧНОЇ ТЕРАПІЇ ТА ЇЇ ЗНАЧЕННЯ ДЛЯ УКРАЇНИ
Matrenitsky, V. L. (2022) · Likarska sprava · doi:10.31640/2706-8803-2022-(3-4)-04 · Cited by 1
Et psykoanalytisk og et postmoderne perspektiv på selv/egoopløsning i en psykedelisk kontekstPreprint
Andersen, S. (2023) · PsyArXiv (OSF Preprints) · doi:10.31234/osf.io/f26ce
Yates, J. R. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-90578-7.00014-1
Caldararo, N. (2022) · Springer eBooks · doi:10.1007/978-3-031-13745-7_1
Metadata
- Authors
- Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P., & Griffiths, R. R.
- Affiliations
- Johns Hopkins University (US)
- Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2014-09-11
- Volume
- 28
- Issue
- 11
- Pages
- 983-992
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- PMC
- PMC4286320
- OpenAlex
- W2122459973
- Cited by
- 914
- References
- 63
- Citations by year
- 2026: 71 · 2025: 130 · 2024: 126 · 2023: 112 · 2022: 121 · 2021: 94 · 2020: 70 · 2019: 33 · 2018: 48 · 2017: 45 · 2016: 46 · 2015: 13 · 2014: 3
- FWCI
- 41.88
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- World Health Organization
- National Institute on Drug Abuse (R01DA003889, T32DA007209)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Smoking Behavior and Cessation
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Keywords
- psilocybin, tobacco dependence, smoking cessation, nicotine dependence, hallucinogens, 5-HT2A receptor agonists, adjunctive therapy, abstinence, treatment safety and feasibility
- MeSH terms
- Attitude, Carbon Monoxide, Combined Modality Therapy, Cotinine, Dose-Response Relationship, Drug, Female, Humans, Male, Middle Aged, Pilot Projects, Psilocybin, Tobacco Use Disorder, Biomarkers, Cognitive Behavioral Therapy, Smoking Cessation, Behavior, Addictive, Treatment Outcome, Serotonin Receptor Agonists, Nicotinic Agonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
